These findings suggest that the combination treatment could potentially counteract the negative effects of the BIM deletion, which is a common genetic variant associated with resistance to EGFR-targeted therapy in NSCLC with EGFR mutations [28]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.